Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIFN-gamma 1b plus standard therapy for candidemia
NL-OMON52806Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon gamma-1b in candidemia and invasive candidiasis (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Time to first negative blood culture. Started Mar 2023; status: recruiting.
02
Drugs
interferon gamma-1b
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NL-OMON52806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52806.